MiMedx Group

MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.

MIMEDX GROUP INC

Recent Gains

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ACON

ALUR

ASST

AVBP

CNOB

DWTX

HSTM

IPHA

LGTY

MDXG

The Marygold Companies, Inc. Common Stock

MGLD

MULN

ONCO

PXLW

RMBI

TVGN

VINC

Why Logility Supply Chain Solutions Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket

Palantir, Salesforce, Okta, Meta, And Tesla: Why These 5 Stocks Are On Investors' Radars Today

ALMS

ALVO

ATHM

BWMX

JBHT

JBLU

TKNO

JB Hunt Transport Posts Weak Earnings, Joins JetBlue Airways And Other Big Stocks Moving Lower In Friday&#39;s Pre-Market Session

Intel, Cleanspark, Super Micro Computer, Upstart, Tesla: Why These 5 Stocks Are On Investors' Radars Today

BBGI

BCAX

ELTX

FOXO

ISPC

LYTS

NATR

NUKK

OFIX

TMCI

TXNM

VIAV

WILC

Why Versus Systems Shares Are Trading Higher By Around 71%; Here Are 20 Stocks Moving Premarket

MiMedx Group Inc

Health Care

Press Releases

General

MIMEDX Points to The New York Times Article on the Vast Benefits of Placental Tissue

MIMEDX to Host Third Quarter 2024 Operating and Financial Results Conference Call on October 30

Earnings

MIMEDX Announces Third Quarter 2024 Operating and Financial Results

MIMEDX to Participate in Upcoming Investor Conferences

MIMEDX's Advocacy to Rein in Runaway Medicare Spend for Skin Substitutes Has Yielded Significant Results with Planned Implementation of LCDs

Legal

MIMEDX Files Patent Infringement Lawsuit Against Surgenex

MIMEDX to Host Fourth Quarter and Full Year 2024 Operating and Financial Results Conference Call on February 26

MIMEDX Announces Fourth Quarter and Full Year 2024 Operating and Financial Results

MIMEDX to Present at TD Cowen 45th Annual Health Care Conference

Ardelyx

Arrowhead Pharmaceuticals, Inc. - Common Stock

Arrowhead Pharma

BioCryst Pharmaceuticals, Inc. - Common Stock

BioCryst Pharma

CareDx

CG Oncology

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics

Dyne Therapeutics

89bio

Geron

GRAIL

IDEAYA Biosciences

Immunocore Holdings plc - American Depositary Shares

Immunocore Holdings

Iovance Biotherapeutics, Inc. - Common Stock

Iovance Biotherapeutics

Mesoblast Limited - American Depositary Shares

Mesoblast

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics

MannKind

Novavax

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals

ARS Pharmaceuticals

Spyre Therapeutics

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics

Vera Therapeutics, Inc. - Class A Common Stock

Vera Therapeutics

Vir Biotechnology

Viridian Therapeutics, Inc. - Common Stock

Viridian Therapeutics

Zymeworks

Cantor Fitzgerald

Craig-Hallum

HC Wainwright & Co.

Lake Street

Mizuho

Comments

MiMedx Group

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga